Anti-atherosclerotic effect of incretin receptor agonists

被引:2
|
作者
Wang, Xin [1 ]
Yang, Xin [1 ]
Qi, Xiaoyan [2 ,3 ]
Fan, Gang [3 ,4 ]
Zhou, Lingzhi [3 ,5 ]
Peng, Zhengliang [6 ]
Yang, Jing [1 ,2 ,3 ]
机构
[1] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Metab & Endocrinol, Hengyang, Hunan, Peoples R China
[2] Shenzhen Nanshan Peoples Hosp, Dept Metab & Endocrinol, Shenzhen, Guangdong, Peoples R China
[3] Shenzhen Univ Hlth Sci Ctr, Affiliated Hosp 6, Shenzhen, Guangdong, Peoples R China
[4] Shenzhen Nanshan Peoples Hosp, Dept Urol, Shenzhen, Guangdong, Peoples R China
[5] Shenzhen Nanshan Peoples Hosp, Dept Pediat, Shenzhen, Guangdong, Peoples R China
[6] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Emergency, Hengyang, Hunan, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
incretin receptor agonists; type 2 diabetes mellitus; cardiovascular disease; atherosclerosis; vasculoprotective effects; DEPENDENT INSULINOTROPIC POLYPEPTIDE; PEPTIDE-1 ANALOG LIRAGLUTIDE; ENDOTHELIAL-CELL DYSFUNCTION; ONCE-WEEKLY SEMAGLUTIDE; SMOOTH-MUSCLE-CELLS; END-PRODUCTS AGES; CARDIOVASCULAR OUTCOMES; DOUBLE-BLIND; ATHEROSCLEROTIC LESIONS; VASCULAR ENDOTHELIUM;
D O I
10.3389/fendo.2024.1463547
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Incretin receptor agonists (IRAs), primarily composed of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide receptor agonists (GIPRAs), work by mimicking the actions of the endogenous incretin hormones in the body. GLP-1RAs have been approved for use as monotherapy and in combination with GIPRAs for the management of type 2 diabetes mellitus (T2DM). In addition to their role in glucose regulation, IRAs have demonstrated various benefits such as cardiovascular protection, obesity management, and regulation of bone turnover. Some studies have suggested that IRAs not only aid in glycemic control but also exhibit anti-atherosclerotic effects. These agents have been shown to modulate lipid abnormalities, reduce blood pressure, and preserve the structural and functional integrity of the endothelium. Furthermore, IRAs have the ability to mitigate inflammation by inhibiting macrophage activation and promoting M2 polarization. Research has also indicated that IRAs can decrease macrophage foam cell formation and prevent vascular smooth muscle cell (VSMC) phenotype switching, which are pivotal in atheromatous plaque formation and stability. This review offers a comprehensive overview of the protective effects of IRAs in atherosclerotic disease, with a focus on their impact on atherogenesis.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice
    Takase, Hiromichi
    Hashimoto, Ayako
    Okutsu, Reiko
    Hirose, Yoshimi
    Ito, Hideki
    Imaizumi, Takashi
    Miyakoda, Goro
    Mori, Toyoki
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2007, 57 (04): : 185 - 191
  • [42] Verbascoside exerts an anti-atherosclerotic effect by regulating liver glycerophospholipid metabolism
    Lei, Peng
    Lu, Jialin
    Yao, Tie
    Zhang, Peng
    Chai, Xin
    Wang, Yuefei
    Jiang, Miaomiao
    FOOD SCIENCE AND HUMAN WELLNESS, 2023, 12 (06) : 2314 - 2323
  • [43] TEMPORAL DIFFERENCES IN ANTI-ATHEROSCLEROTIC EFFECT OF ESTROGEN IN ALBINO-RATS
    MARTIN, DD
    HILBURN, F
    THIGPEN, A
    AMERICAN ZOOLOGIST, 1978, 18 (03): : 572 - 572
  • [44] Mechanisms Underlying the Anti-Atherosclerotic Effects of EGCG
    Wang, Lili
    Pan, Qun
    Tang, Chunlian
    CURRENT MOLECULAR MEDICINE, 2025,
  • [45] Animal models to evaluate anti-atherosclerotic drugs
    Priyadharsini, Raman P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 (04) : 329 - 340
  • [46] Anti-atherosclerotic effects of the hexapeptide angiotensin IV
    Vinh, Antony
    Widdop, Robert
    Gaspari, Tracey
    FASEB JOURNAL, 2008, 22
  • [47] Laboratory surrogates for anti-atherosclerotic drug development
    Stein, E
    AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (4A): : 21A - 26A
  • [48] ANTI-ATHEROSCLEROTIC EFFECTS OF SQUALENE SYNTHASE INHIBITORS
    Tavridou, A.
    Manolopoulos, V.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [49] Potentiality of ACAT inhibitors as anti-atherosclerotic drugs
    Shirahase, Hiroaki
    Kunishiro, Kazuyoshi
    Miike, Tomohiro
    Kanda, Mamoru
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2007, 127 : 44 - 47
  • [50] Novel Targets and Biomarkers for Anti-atherosclerotic Therapy
    Bobryshev, Yuri V.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (33) : 5837 - 5839